Analyst Research Report Snapshot

Title:

Dr. Reddy's Labs (DRRD) - Qtr. Updfate - Dtd. - February 14, 2013

Price:

$35.00

Provider:

Axis Capital Limited

Date:

15 Feb 2013

Pages:

4

Type:

AcrobatPDF

Companies referenced:

REDY.NS

Available for Immediate Download
Summary:

Dr. Reddy’s Lab (DRL) reported Q3FY13 PAT at Rs 3.8 bn (down 22% YoY), which was below our estimate of Rs 5 bn. This was primarily due to: (a) forex loss of Rs 550 mn on cash flow hedges and Rs 80 mn net MTM loss and (b) higher SG&A (increased by Rs 580 mn QoQ). Increase in SG&A was due to higher spending on product launches and ~Rs 70 mn one-time rationalization cost in Germany. YoY fall in PAT was also due to USD 99 mn of one-off Zyprexa revenue in Q3FY12. Maintain BUY with target price of Rs 2,100 (12% upside from CMP of Rs 1,878) We believe strong presence in US (65 pending ANDAs; ramp-up in recent launches), 20% CAGR in high margin Russia business, and recovery in India (13% CAGR vs. 10% in FY12) would help DRL post 18% CAGR in core earnings over next two years. Maintain BUY with TP of Rs 2,100 – base business at Rs 2,087 (18x FY15E base EPS of Rs 116) and pipeline at Rs 13/share. At CMP, the stock trades at 18x FY14E EPS of Rs 106 and 16x FY15E EPS of Rs 120. Revenue (Rs 29 bn; up 3% YoY) in line with estimate; expect Q4 to be better  Revenue growth adjusted for one-off Zyprexa revenue in Q3FY12 was up 24% YoY  Management indicated benefits of market share ramp-up in key products – Metoprolol and Atorva – would be visible from Q4 (market share in Metaprolol has increased to ~15% from Jan ’13).  Russia/ CIS grew 32% YoY (26% in local currency) to Rs 4.4 bn driven by: (a) low base in Q2FY13, (b) better seasonal off-take, and (c) product launches  Delay in dispatch of high-value products led to 10% sequential decline in Pharmaceuticals Services and Active Ingredients (PSAI) revenue. Management indicated strong growth in Q4. PSAI gross margin fell to 29%; expect recovery from Q4: Management indicated gross margin in PSAI segment reduced to 29% in Q3 (35% in Q2) on (a) delay in dispatch of high-value batches and (b) pricing pressure in few large products. However, gross margin shall improve to 32-33% with launch of new products. Regards, Deepak Khetan (Asst VP – Life Sciences) Institutional Equity Research Axis Capital Ltd. Tel: +91 22 4325 1132

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.